RESUMEN
The world has witnessed a revolution in therapeutics with the development of biological medicines such as antibodies and antibody fragments, notably nanobodies. These nanobodies possess unique characteristics including high specificity and modulatory activity, making them promising candidates for therapeutic applications. Identifying their binding mode is essential for their development. Experimental structural techniques are effective to get such information, but they are expensive and time-consuming. Here, we propose a computational approach, aiming to identify the epitope of a nanobody that acts as an agonist and a positive allosteric modulator at the rat metabotropic glutamate receptor 5. We employed multiple structure modeling tools, including various artificial intelligence algorithms for epitope mapping. The computationally identified epitope was experimentally validated, confirming the success of our approach. Additional dynamics studies provided further insights on the modulatory activity of the nanobody. The employed methodologies and approaches initiate a discussion on the efficacy of diverse techniques for epitope mapping and later nanobody engineering.
Asunto(s)
Aprendizaje Profundo , Epítopos , Receptor del Glutamato Metabotropico 5 , Anticuerpos de Dominio Único , Receptor del Glutamato Metabotropico 5/química , Receptor del Glutamato Metabotropico 5/metabolismo , Receptor del Glutamato Metabotropico 5/inmunología , Anticuerpos de Dominio Único/química , Anticuerpos de Dominio Único/inmunología , Epítopos/inmunología , Epítopos/química , Animales , Ratas , Modelos Moleculares , Mapeo Epitopo/métodos , Simulación de Dinámica Molecular , Conformación ProteicaRESUMEN
A 30-year-old woman had 5 days of visual hallucinations, nystagmus, memory impairment and mutism. On examination, she was disorientated with reduced attention span, gaze-evoked nystagmus, paratonia and abnormal frontal reflexes. Cerebrospinal fluid (CSF) showed 80 cells, protein 0.41 g/L and glucose 3.2 mmol/L (plasma glucose 5.0 mmol/L). MR scan of the brain showed involvement of limbic and extra-limbic regions and brainstem. Commercial cell-based assays were negative, but tissue-based assays showed neuropil staining, and cell-based assays for anti-metabotropic glutamate receptor 5 (mGluR5) antibodies were positive in serum and CSF. Six months later, she was diagnosed with Hodgkin's lymphoma. This case emphasises the broader clinical spectrum of anti-mGluR5 encephalitis, challenging its initial characterisation as Ophelia syndrome. It underscores the significance of interpreting commercial cell-based assays and advocates for tissue-based assay testing followed by cell-based assay testing in serum and CSF for diagnosing rare autoimmune encephalitis.
Asunto(s)
Autoanticuerpos , Encefalitis , Receptor del Glutamato Metabotropico 5 , Humanos , Femenino , Adulto , Receptor del Glutamato Metabotropico 5/inmunología , Autoanticuerpos/sangre , Autoanticuerpos/líquido cefalorraquídeo , Autoanticuerpos/inmunología , Encefalitis/inmunología , Encefalitis/diagnóstico , Encefalitis/sangre , Enfermedad de Hodgkin/complicaciones , Enfermedad de Hodgkin/inmunologíaRESUMEN
La encefalitis autoinmune es una entidad heterogénea en cuanto a su presentación clínica y pronóstico. Es frecuente que este cuadro presente síntomas psiquiátricos por lo que es habitual la intervención de los servicios de psiquiatría tanto en el proceso diagnóstico como en el manejo sintomático. El curso de la enfermedad suele ser agudo o rápidamente progresivo motivo por el cual es esencial la detección precoz de esta enfermedad con el fin de realizar las exploraciones complementarias y el tratamiento etiológico. Describimos el caso de un varón de 49 años, sin antecedentes psiquiátricos que presenta sintomatología maniforme en urgencias pero que a las pocas horas de ingresar en la unidad de agudos presenta disminución del nivel de consciencia y fiebre. Las exploraciones complementarias permiten orientarlo como encefalitis autoinmune por anticuerpos contra el receptor metabotrópico de glutamato 5. La psiquiatría de interconsulta participa en el manejo sintomático del paciente
Autoimmune encephalitis is a heterogeneous entity in terms of its symptoms and prognosis. As the clinical presentation frequently includes psychiatric symptoms, the intervention of psychiatric services is usual in the diagnostic process, as well as in the management of the symptoms. The course of the disease is usually acute or rapidly progressive, making the early detection of this disease essential in patients in order to perform the complementary tests and to treat the origin. The case is presented of a 49 year-old man, with no psychiatric history, who presents with maniac symptoms in the emergency room. A few hours after being admitted to the inpatient unit he presents with decrease in consciousness level and fever. Complementary tests led to the diagnosis of autoimmune encephalitis with antibodies against the metabotropic receptor of glutamate 5. The psychiatric approach for symptomatic treatment was made by joint consultation
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Receptor del Glutamato Metabotropico 5/inmunología , Encefalitis/complicaciones , Trastornos Psicóticos Afectivos/etiología , Encefalitis/inmunología , Enfermedades Autoinmunes/complicaciones , Líquido Cefalorraquídeo , Diagnóstico DiferencialRESUMEN
A 68-years-old Hispanic man, complained of night sweats, low grade fewer, unexplained weight loss, and memory problems over 3 months. Abdominal tomography showed multiple intra-abdominal adenopathy and biopsy confirmed classic Hodgkin's lymphoma. He commenced treatment with chemotherapy. Three months later, he had acute onset of inattention, auditory hallucinations and alterations of anterograde memory. The patient developed psychomotor agitation, unresponsive to a combination of neuroleptics and benzodiazepines. Brain MRI showed a small established cerebellar infarction. Electroencephalogram was normal. Tests for toxic metabolic encephalopathy were negative. One oligoclonal IgG bands was found in the Cerebrospinal fluid (CSF), which was not observed in corresponding serum, but cell count and protein were normal. Extensive testing for infectious encephalitis was unremarkable. CSF testing for commercially available neural and non-neural autoantibodies was negative. The patient fulfilled the Gultekin diagnostic criteria for paraneoplastic limbic encephalitis and methylprednisolone IV 1g/d for 5 days was given. He recovered rapidly, with progressive improvement in memory and psychomotor agitation. After treatment commenced, results for antibodies to mGluR5 in CSF taken prior to treatment were returned as positive. mGluR5 is found on post-synaptic terminals of neurons and microglia and is expressed primarily in the hippocampus and amygdala. This case highlights the difficulties in diagnosing this type of encephalitis: the CSF did not show pleocytosis, the MRI showed only chronic change and the electroencephalogram was normal. The dramatic recovery after methylprednisolone help to better characterized the clinical spectrum of auto-immune encephalitis. Diagnosing anti mGlutR5 encephalitis may lead to potentially highly effective treatment option and may anticipate the diagnostic of a cancer. A high index of suspicion is needed to avoid missed diagnosis. In patients with unexplained encephalitis, testing for antibodies to mGluR5 in CSF and serum should be considered. When there is a reasonable index of suspicion of auto-immune encephalitis, treatment should not be delayed for the antibody results.
Asunto(s)
Autoanticuerpos/líquido cefalorraquídeo , Encefalitis/líquido cefalorraquídeo , Encefalitis/diagnóstico , Enfermedad de Hashimoto/líquido cefalorraquídeo , Enfermedad de Hashimoto/diagnóstico , Inmunoglobulina G/líquido cefalorraquídeo , Encefalitis Límbica/diagnóstico , Receptor del Glutamato Metabotropico 5/inmunología , Anciano , Encefalitis/tratamiento farmacológico , Enfermedad de Hashimoto/tratamiento farmacológico , Enfermedad de Hodgkin/diagnóstico , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Encefalitis Límbica/líquido cefalorraquídeo , Encefalitis Límbica/tratamiento farmacológico , Masculino , Metilprednisolona/uso terapéuticoRESUMEN
OBJECTIVE: To report the clinical features of 11 patients with metabotropic glutamate receptor 5 (mGluR5) antibody-associated encephalitis, immunoglobulin G (IgG) subclass, and effects of the antibodies on neuronal mGluR5 clusters. METHODS: Clinical information was retrospectively obtained from referring physicians. Antibodies to mGluR5 and IgG subclasses were determined with brain immunohistochemistry and cell-based assays. The effects of the antibodies were examined on rat hippocampal neurons with reported techniques. RESULTS: From January 2005 to May 2017, 11 patients (median age 29 years, range 6-75 years, 5 female) were identified. The main clinical features were psychiatric (10), cognitive (10), movement disorders (7), sleep dysfunction (7), and seizures (6). Median modified Rankin Scale score at the peak of the disease was 4; 4 patients required intensive care. Five patients had Hodgkin lymphoma, and 1 had small cell lung cancer. CSF showed pleocytosis (median white blood cell count 22 mm3) in all patients; brain MRI was abnormal in 5, involving limbic (1) or extralimbic (4) regions. Treatments included immunotherapy and/or oncologic therapy; at the last follow-up (median 48 months), 6 patients had complete and 5 had partial recovery. Neurologic relapse occurred in 2 patients. Antibodies were IgG1 alone (4 of 9) or in combination with IgG2 (1 of 9), IgG3 (3 of 9), or both (1). Patients' IgG caused a significant and specific decrease of cell-surface synaptic and extrasynaptic mGluR5 without altering the levels of postsynaptic density protein 95. CONCLUSIONS: Anti-mGluR5 encephalitis associates with a complex neuropsychiatric syndrome, not restricted to limbic encephalitis, and can occur without tumor. Patients respond to treatment, but relapses can occur. The antibodies have pathogenic effects altering the levels of cell-surface mGluR5.
Asunto(s)
Autoanticuerpos/inmunología , Encefalitis/inmunología , Receptor del Glutamato Metabotropico 5/inmunología , Adolescente , Adulto , Anciano , Niño , Femenino , Células HEK293 , Humanos , Masculino , Persona de Mediana Edad , Neuronas/inmunología , Neuronas/metabolismo , Receptor del Glutamato Metabotropico 5/metabolismo , Estudios Retrospectivos , Adulto JovenRESUMEN
Therapeutic apheresis has emerged as a major treatment option for autoantibody-associated inflammatory diseases of the nervous system. This includes patients with autoimmune encephalitides caused by antibodies against neuronal proteins. Plasma exchange (PE) and immunoadsorption (IA) constitute two possibilities to eliminate pathogenic antibodies from patients' plasma, but their efficacy and safety has not been prospectively assessed in larger patient groups of autoimmune encephalitides. In a prospective observational case control study, we, therefore, investigated the disease courses and treatment effects of 21 patients with autoimmune encephalitis associated with NMDAR, LGI1, CASPR2, GAD, mGluR5 and Hu antibodies. Patients were randomly assigned to receive PE (n = 11) or IA (n = 10). Symptoms were evaluated using the modified Rankin Scale (mRS). Side effects or adverse events were recorded. Both interventions, IA (p = 0.014) and PE (p = 0.01), resulted in significant reduction of the median mRS. With IA, 60 % of the patients improved clinically by at least 1 mRS score, none worsened. PE led to a comparable symptom reduction in 67 % of the cases. During 83 PE sessions, three adverse events were documented, while no side effects occurred under IA. Symptom improvement was significantly associated with younger age (r = -0.58), but not with disease duration. Therapeutic apheresis was most effective for neuronal surface antigens (83.3 %), followed by intracellular-synaptic antigens (66.7 %). Both IA and PE resulted in moderate to marked clinical improvement, with a low rate of adverse events. Apheresis is well tolerated and effective also as first-line therapy in autoimmune encephalitis, particularly in patients with antibodies targeting neuronal surfaces.
Asunto(s)
Encefalitis/inmunología , Encefalitis/terapia , Enfermedad de Hashimoto/inmunología , Enfermedad de Hashimoto/terapia , Inmunoterapia/métodos , Intercambio Plasmático/métodos , Adolescente , Adulto , Factores de Edad , Anciano , Anticuerpos/metabolismo , Proteínas ELAV/inmunología , Femenino , Glutamato Descarboxilasa/inmunología , Humanos , Técnicas de Inmunoadsorción , Péptidos y Proteínas de Señalización Intracelular , Masculino , Proteínas de la Membrana/inmunología , Persona de Mediana Edad , Proteínas del Tejido Nervioso/inmunología , Proyectos Piloto , Proteínas/inmunología , Receptor del Glutamato Metabotropico 5/inmunología , Receptores de N-Metil-D-Aspartato/inmunología , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenAsunto(s)
Encefalitis Límbica/inmunología , Prosopagnosia/tratamiento farmacológico , Prosopagnosia/inmunología , Receptor del Glutamato Metabotropico 5/inmunología , Adulto , Autoanticuerpos/sangre , Autoanticuerpos/líquido cefalorraquídeo , Femenino , Humanos , Inmunoglobulina G/sangre , Inmunoglobulina G/líquido cefalorraquídeo , Encefalitis Límbica/sangre , Encefalitis Límbica/líquido cefalorraquídeo , Encefalitis Límbica/complicaciones , Encefalitis Límbica/tratamiento farmacológico , Encefalitis Límbica/terapia , Metilprednisolona/uso terapéutico , Intercambio Plasmático , Prosopagnosia/sangre , Prosopagnosia/líquido cefalorraquídeo , Prosopagnosia/complicaciones , Prosopagnosia/terapia , Receptor del Glutamato Metabotropico 5/efectos de los fármacosRESUMEN
PURPOSE OF REVIEW: This review describes the main types of autoimmune encephalitis with special emphasis on those associated with antibodies against neuronal cell surface or synaptic proteins, and the differential diagnosis with infectious encephalitis. RECENT FINDINGS: There is a continuous expansion of the number of cell surface or synaptic proteins that are targets of autoimmunity. The most recently identified include the metabotropic glutamate receptor 5 (mGluR5), dipeptidyl-peptidase-like protein-6 (DPPX), and γ-aminobutyric acid-A receptor (GABAAR). In these and previously known types of autoimmune encephalitis [N-methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), γ-aminobutyric acid-B receptor (GABABR), leucine-rich glioma inactivated protein 1 (LGI1), contactin-associated protein-like 2 (CASPR2)], the prodromal symptoms or types of presentations often suggest a viral encephalitis. We review here clues that help in the differential diagnosis with infectious encephalitis. Moreover, recent investigations indicate that viral encephalitis (e.g., herpes simplex) can trigger synaptic autoimmunity. In all these disorders, immunotherapy is usually effective. SUMMARY: Autoimmune encephalitis comprises an expanding group of potentially treatable disorders that should be included in the differential diagnosis of any type of encephalitis. VIDEO ABSTRACT: http://links.lww.com/CONR/A25,